Method for preparing oxadiazolylaminobenzodiazepine heptane derivatives

By employing a multi-step method to prepare compound (I), the problems of high cost and limited effectiveness of existing RSV therapeutics are solved, providing a high-yield and high-purity RSV inhibitor suitable for the treatment of RSV infection.

CN122094944APending Publication Date: 2026-05-26ENANTA PHARM INC
View PDF 12 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
ENANTA PHARM INC
Filing Date
2024-08-08
Publication Date
2026-05-26

AI Technical Summary

Technical Problem

Existing RSV treatments such as palizumab are costly and have limited efficacy, and existing compounds have limitations in treating RSV infection, necessitating the development of new, highly effective RSV inhibitors.

Method used

The method for preparing compound (I) involves reacting compound (A) with 1,1'-carbonyldiimidazole, followed by reaction with compound (W), then reaction with a dehydrating agent, using specific solvent and temperature conditions, and finally purification by recrystallization, thereby improving the yield and purity of the product.

Benefits of technology

Compound (I) with high yield and high purity is provided as a potent RSV inhibitor suitable for the treatment of RSV infection, especially for high-risk populations.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122094944A_ABST
    Figure CN122094944A_ABST
Patent Text Reader

Abstract

This invention relates to a method for preparing compound (I) or a pharmaceutically acceptable salt or solvate thereof. In particular, such a method comprises the dehydration cyclization of a 1,2-diacylhydrazine intermediate to form the corresponding 1,3,4-oxadiazole, wherein the dehydration cyclizing agent may be N,N-dimethylaminosulfonyl chloride, N-(triethylammonium sulfonyl)carbamate, phosphorus trichloride, or phosphorus pentachloride, resulting in increased product yield and purity compared to known methods. Compound (I) and pharmaceutical compositions thereof can be used as respiratory syncytial virus (RSV) inhibitors.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • RSV polymerase inhibitors

    WO2005042530A1

  • Anti-RSV compounds

    WO2011005842A1

  • Compounds for treating respiratory syncytial virus infections

    WO2012068622A1

  • Pyrazolo[1,5-a]pyrimidines as antiviral agents

    WO2013096681A1

  • 4 - substituted 1, 3 - dihydro - 2h - benzimidazol - 2 - one derivatives substituted with benzimidazoles as respiratory syncytial virus antiviral agents

    WO2013186332A1